Page last updated: 2024-10-17

aminocaproic acid and Myeloproliferative Disorders

aminocaproic acid has been researched along with Myeloproliferative Disorders in 1 studies

Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.

Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Culpeper, KS1
Nousari, HC1

Other Studies

1 other study available for aminocaproic acid and Myeloproliferative Disorders

ArticleYear
Purpura fulminans.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Autoantibodies; Humans; IgA Vasculitis; Male; Myel

2003